Is bortezomib an effective treatment for indolent or mantle-cell non-Hodgkin's lymphoma?

被引：2
|
作者：
Coiffier, B [1 ]
机构：
[1] Hospices Civils Lyon, Dept Hematol, Lyon, France
来源：
NATURE CLINICAL PRACTICE ONCOLOGY | 2005年 / 2卷 / 08期
关键词：
bortezomib; non-Hodgkin's lymphoma; mantle-cell lymphoma;
D O I：
10.1038/ncponc0229
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：388 / 389
页数：2
相关论文
共 50 条
  • [1] Is bortezomib an effective treatment for indolent or mantle-cell non-Hodgkin's lymphoma?
    Bertrand Coiffier
    Nature Clinical Practice Oncology, 2005, 2 : 388 - 389
  • [2] Primary mantle-cell non-Hodgkin’s lymphoma of the tongue
    Salvatore Guastafierro
    Umberto Falcone
    Maria Celentano
    Salvatore Cappabianca
    Amerigo Giudice
    Giuseppe Colella
    International Journal of Hematology, 2008, 88 : 206 - 208
  • [3] The emerging role of Bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas
    O'Connor O.A.
    Current Treatment Options in Oncology, 2004, 5 (4) : 269 - 281
  • [4] Primary mantle-cell non-Hodgkin's lymphoma of the tongue
    Guastafierro, Salvatore
    Falcone, Umberto
    Celentano, Maria
    Cappabianca, Salvatore
    Giudice, Amerigo
    Colella, Giuseppe
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2008, 88 (02) : 206 - 208
  • [5] Promising activity of the proteasome inhibitor bortezomib (velcade) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
    O'Connor, O
    Wright, J
    Moskowitz, CH
    Muzzy, J
    MacGregor-Cortelli, B
    Hamlin, P
    Straus, D
    Trehu, E
    Schenkein, DP
    Zelenetz, AD
    BLOOD, 2003, 102 (11) : 636A - 636A
  • [6] Phase II results of bendamustine in combination with rituximab in relapsed indolent and mantle-cell non-hodgkin's lymphoma
    van der Jagt, Richard H.
    Cohen, Philip
    Cheson, Bruce
    Tulpule, Anil
    Herst, Jordan A.
    Lemieux, Bernard
    Schwartzberg, Lee S.
    Robinson, K. Sue
    Oliver, Jennifer W.
    Williams, Michael E.
    CANCER INVESTIGATION, 2007, 25 : 35 - 36
  • [7] Phase II results of bendamustine in combination with rituximab in relapsed indolent and mantle-cell non-Hodgkin's lymphoma.
    Van der Jagt, Richard H.
    Cohen, Philip
    Cheson, Bruce D.
    Tulpule, Anil
    Herst, Jordan A.
    Lemieux, Bernard
    Schwartzberg, Lee S.
    Robinson, Katherine Sue
    Oliver, Jennifer W.
    Williams, Michael E.
    BLOOD, 2006, 108 (11) : 766A - 766A
  • [8] The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
    Friedberg, Jonathan W.
    Vose, Julie M.
    Kelly, Jennifer L.
    Young, Faith
    Bernstein, Steven H.
    Peterson, Derick
    Rich, Lynn
    Blumel, Susan
    Proia, Nicole K.
    Liesveld, Jane
    Fisher, Richard I.
    Armitage, James O.
    Grant, Steven
    Leonard, John P.
    BLOOD, 2011, 117 (10) : 2807 - 2812
  • [9] Bortezomib for the treatment of non-Hodgkin's lymphoma
    Bose, Prithviraj
    Batalo, Michael S.
    Holkova, Beata
    Grant, Steven
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (16) : 2443 - 2459
  • [10] Bortezomib treatment for patients with mantle-cell lymphoma
    Tanday, Sanjay
    LANCET ONCOLOGY, 2015, 16 (04): : E162 - E162
12345